Statins for Healthy Adults: What Both Sides Claim and What the Strongest Trials Show
Few drugs have been argued over as long or as loudly as statins. One side says they are a cheap, proven way to prevent heart attacks and strokes in people who have never had one. The other says the benefit for a healthy adult is small, the side effects are underreported, and millions of people are taking a daily pill for little gain. This follows our format of setting out what both sides claim and then checking the strongest sources, in the same spirit as our fluoridation review. Here is what each side actually claims, and what the strongest available evidence shows when you check it.
What the pro-statin side claims
Cardiologists point out that statins lower LDL cholesterol by roughly 30 to 50 percent depending on dose and drug, and that this translates into fewer heart attacks and strokes in large randomised trials. The evidence base is unusually deep: dozens of trials covering well over 100,000 patients. The consensus bodies, including the US guideline writers and the UK’s NICE, recommend statins for people whose ten-year cardiovascular risk crosses a threshold, even if they have never had an event, because the trials showed a reduction in events in exactly that population.
They also argue that serious side effects are rare. Muscle pain is the most commonly reported problem, but blinded trial analyses suggest only a small share of it is caused by the drug itself. Rhabdomyolysis, the catastrophic muscle complication, occurs in roughly 1 in 10,000 people per year of use or less. On this view, a pill that costs a few pounds a month and cuts a healthy adult’s already small risk is a good trade.
What the sceptical side claims
The sceptics do not usually dispute that statins lower cholesterol or that they help people who already have heart disease. Their argument is about healthy adults, where the absolute numbers look very different. If your ten-year risk of a heart attack is 3 percent and the drug cuts relative risk by about a quarter, you have avoided roughly a 0.75 percent chance of an event. Put another way, well over a hundred people need to take the drug daily for years for one to avoid a heart attack, and most of those people would never have had one anyway.
They add that statins carry a small increase in new-onset type 2 diabetes, shown consistently across the trial data, and that trial side-effect reporting was built in an era when muscle symptoms were actively screened out in some studies. They also argue that the absolute risk reduction, not the relative one, is the number a patient needs, and that guidelines were written by panels with industry ties, an argument that has been examined and debated in the medical press for over a decade.
What the strongest evidence actually shows
Strip away the noise and three findings hold up across the best sources.
First, statins do reduce cardiovascular events in people without existing disease. That is not marketing. Meta-analyses of randomised trials in this population show a relative risk reduction of roughly 25 percent for major vascular events per mmol/L reduction in LDL, sustained over about five years of follow-up. The effect is real, moderate, and consistent.
Second, the absolute benefit depends almost entirely on your starting risk. For a 45-year-old non-smoker with normal blood pressure, the number needed to treat to prevent one event runs into the hundreds per year of benefit. For a 65-year-old smoker with high blood pressure, it can drop to below 50. The drug is the same. The baseline risk is what decides whether it is worth taking. This single point dissolves most of the argument: the two sides are often describing different patients.
Third, the main real-world downside is not the dramatic one. Rhabdomyolysis is rare. The diabetes signal is real but small, on the order of one extra case per several hundred users per year in the trials. The practical complaint is muscle pain and fatigue, which affects somewhere between roughly 1 in 20 and 1 in 10 users in observational data, while blinded rechallenge studies suggest a substantial share of it is expectation rather than pharmacology. Both things can be true: the drug causes some muscle symptoms, and the symptom is also over-attributed to the drug.
Which statin, and does the choice matter?
Part of the public argument is muddied by treating statins as one drug. They are not. Simvastatin, the oldest cheap generic, is the weakest at common doses and interacts with several other medicines. Atorvastatin and rosuvastatin are stronger, need no evening timing, and carry most of the modern evidence. When trials show benefit at “high intensity” dosing, they mean these two. A patient told “statins did not work for a friend” may be comparing 20mg simvastatin against 40mg atorvastatin, which is roughly a threefold difference in LDL reduction. Comparing like with like matters more than most headline rows acknowledge.
The honest conclusion
A defensible summary, and one that both serious sides can sign: statins give a genuine but modest relative risk reduction to healthy adults. Whether that modest reduction is worth a daily pill is a personal calculation that depends on your measured ten-year risk, your own tolerance for the drug, and how much you value avoiding a rare event decades out. Anyone quoting only the relative number, or only the absolute one, is selling you a side.
Sources and their ratings
The evidence tier here is strong on the core question: large randomised trials and their meta-analyses sit at four stars, statistics drawn directly from trial datasets at five. The guideline recommendations sit at three to four stars, because they involve judgement calls about thresholds. The conflict-of-interest arguments around guideline panels sit at two to three stars: documented, but contested and often used to imply more than the documents show.